Albumin is given intravenously to restore or maintain blood volume, support blood pressure, and help the body manage fluid distribution in conditions where its natural albumin levels have dropped dangerously low. It is one of the most commonly prescribed blood-derived products in hospitals worldwide, used across liver disease, sepsis, burns, kidney disorders, and certain specialized procedures. But albumin is not just a simple fluid top-up. Research over the past two decades has revealed that it does far more than expand blood volume, and the clinical situations where it genuinely helps are more specific than many people realize.
What Albumin Actually Does in Your Body
Albumin is the most abundant protein in your blood, making up roughly half of all plasma protein. Your liver produces about 10 to 12 grams of it per day, and each molecule circulates for roughly 25 days before being broken down or excreted.1PubMed Central. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements Its most well-known job is maintaining oncotic pressure, the force that keeps fluid inside your blood vessels rather than leaking out into surrounding tissues.2Alimentary Pharmacology & Therapeutics. Review article: albumin as a drug—biological effects of albumin unrelated to oncotic pressure When albumin drops, fluid seeps into tissues and body cavities, causing swelling and dangerous fluid shifts.
But albumin also acts as a molecular taxi. It binds and transports hormones, fatty acids, metals, and many medications. In critically ill patients whose albumin is low, drugs that normally hitch a ride on albumin can behave unpredictably, sometimes reaching toxic levels in their unbound form or clearing too quickly to be effective.3PubMed. Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients Beyond transport, albumin helps protect blood vessel walls from inflammation, scavenges harmful oxidative molecules, and can even bind bacterial toxins, giving it a mild immune-support role.4PubMed Central. Albumin as a drug: its biological effects beyond volume expansion These “non-oncotic” properties are part of why simply swapping in a cheaper salt-water solution does not always produce the same clinical results.
Liver Disease Is Where the Evidence Is Strongest
If there is one area of medicine where albumin has proven its worth beyond reasonable doubt, it is advanced liver disease. A failing liver produces less albumin, and patients with decompensated cirrhosis often develop dangerously low levels. Three specific liver-related scenarios have solid trial evidence supporting albumin use.
Large-Volume Paracentesis
Patients with cirrhosis frequently accumulate liters of fluid in the abdomen, a condition called ascites. When doctors drain large volumes of that fluid, the sudden shift in pressure can cause a drop in blood flow to vital organs, a problem known as paracentesis-induced circulatory dysfunction. Albumin infusion during the procedure is the standard preventive measure.5Egyptian Liver Journal. Paracentesis-induced circulatory dysfunction: are there albumin alternatives? There is even pilot-level evidence that half the standard albumin dose may be sufficient, which matters given the cost.6PubMed. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study
Spontaneous Bacterial Peritonitis
When the fluid in the abdomen of a cirrhosis patient becomes infected without an obvious surgical cause, the condition is called spontaneous bacterial peritonitis, or SBP. Antibiotics alone clear the infection, but the kidneys often take a severe hit in the process. A landmark trial published in the New England Journal of Medicine found that adding albumin to antibiotic treatment cut kidney failure from about a third of patients down to roughly one in ten, and in-hospital deaths dropped from 29 percent to 10 percent.7PubMed. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis A later meta-analysis pooling several trials confirmed those findings: kidney damage occurred in about 31 percent of patients on antibiotics alone versus roughly 8 percent of those who also received albumin, and mortality dropped from about 35 percent to 16 percent.8PubMed. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials Few interventions in liver medicine show that size of survival benefit.
Hepatorenal Syndrome
When cirrhosis becomes severe enough to shut down kidney function indirectly, the result is hepatorenal syndrome. The standard treatment pairs albumin with a drug called terlipressin, a vasoconstrictor that redirects blood flow toward the kidneys. A phase 3 trial found that terlipressin plus albumin reversed the condition in about 32 percent of patients, compared with 17 percent on placebo plus albumin.9PubMed. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome Albumin alone is not enough to fix hepatorenal syndrome, but it is a necessary part of the combination that works.
Long-Term Albumin in Cirrhosis
A more recent and provocative line of research asks whether giving albumin regularly over months, not just during crises, might change the course of decompensated cirrhosis altogether. The Italian ANSWER trial randomized outpatients with cirrhosis and ascites to standard care with or without weekly albumin infusions and found that the albumin group lived longer overall.10PubMed. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial A post hoc analysis of the same trial looked specifically at patients who also had insulin-treated type 2 diabetes. In that subgroup, survival at the end of the study was 86 percent in the albumin group versus 57 percent on standard care, alongside fewer infections, less kidney dysfunction, and less need for paracentesis.11PubMed. Long-term albumin improves the outcomes of patients with decompensated cirrhosis and diabetes mellitus: Post hoc analysis of the ANSWER trial The idea that albumin might work as a disease-modifying treatment rather than just a crisis intervention is still being tested, but the early data is striking.
Albumin in Sepsis and Septic Shock
Outside liver disease, the most debated use of albumin is in sepsis, the body’s overwhelming response to infection. Patients in septic shock lose enormous amounts of fluid from their bloodstream as their capillaries become leaky. Restoring that volume is essential, and the question is whether albumin does it better than plain saline or other crystalloid solutions.
The evidence here is suggestive but not as clean-cut as in liver disease. A post hoc analysis of a large Australian and New Zealand trial found that patients with severe sepsis who received albumin had a lower adjusted risk of death compared to those given saline.12PubMed. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis A meta-analysis of randomized trials found a statistically significant reduction in 90-day mortality specifically among patients with septic shock who were resuscitated with albumin versus crystalloid fluids.13Critical Care. Comparison of the effects of albumin and crystalloid on mortality in adult patients with severe sepsis and septic shock: a meta-analysis of randomized clinical trials Another systematic review and meta-analysis found a pooled reduction in mortality associated with albumin resuscitation in sepsis.14Critical Care Medicine. The role of albumin as a resuscitation fluid for patients with sepsis: A systematic review and meta-analysis
But translating these findings into everyday practice has been tricky. A more recent randomized trial targeting albumin replacement in septic shock found that more than half the patients in the albumin group never actually reached the target blood albumin level during treatment, despite continuous infusions.15JAMA Network Open. Albumin Replacement Therapy in Septic Shock: A Randomized Clinical Trial That difficulty in hitting the target underscores how rapidly critically ill bodies consume or leak albumin. The trend across the evidence favors albumin in severe sepsis and especially septic shock, but the benefit is more modest than in SBP, and there is still debate about exactly which patients benefit most and when during their illness to give it.
Burns and Fluid Overload
Major burns cause massive fluid loss through damaged skin and leaky capillaries. Standard burn resuscitation involves giving large volumes of crystalloid solution, but a well-recognized problem called “fluid creep” occurs when patients receive too much crystalloid. The excess fluid builds up in tissues, causing swelling that can compromise breathing, increase abdominal pressure, and worsen outcomes.16PubMed. The phenomenon of “fluid creep” in acute burn resuscitation Adding albumin (or other colloids) to the resuscitation strategy is one of the main approaches to keeping total fluid volumes under control.17PubMed Central. Acute burn resuscitation and fluid creep: it is time for colloid rehabilitation The logic is straightforward: because albumin stays in the bloodstream longer than crystalloid does, you need less total volume to achieve the same circulatory support.
How Albumin Compares to Other Fluids
In a healthy person, colloids like albumin expand blood volume more efficiently than crystalloid solutions. But in critically ill patients, whose capillaries are already leaky, that advantage shrinks because some of the albumin escapes into tissues anyway. Experimental evidence suggests that albumin still maintains better plasma volume expansion than other colloids, like starch-based solutions, even when capillary permeability is increased.18PubMed. Role of albumin, starches and gelatins versus crystalloids in volume resuscitation of critically ill patients
That last point matters because starch-based volume expanders (hydroxyethyl starch, or HES) fell dramatically out of favor after studies linked them to kidney damage. A meta-analysis found that concentrated albumin solutions actually reduced the odds of acute kidney injury by about 76 percent, while concentrated starch solutions nearly doubled those odds.19Critical Care. Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials That split is stark and has pushed many intensive care units toward albumin as the colloid of choice when one is needed. Still, albumin is dramatically more expensive than saline. One hospital analysis found that implementing a protocol to minimize albumin use in post-cardiac surgery patients reduced albumin consumption with no measurable difference in safety or efficacy outcomes, suggesting that in some routine situations, the cheaper option is perfectly fine.20Annals of Pharmacotherapy. Albumin Versus Crystalloids in Postcardiac Surgery Fluid Resuscitation: A Cost and Safety Analysis
Kidney Disease and Stubborn Swelling
In nephrotic syndrome, the kidneys lose massive amounts of protein into the urine, and albumin levels in the blood plummet. The resulting edema can be severe and resistant to diuretics. Giving albumin alongside a loop diuretic like furosemide can boost urine output by improving the delivery of the diuretic to the kidneys.21PubMed Central. Albumin and Furosemide Combination for Management of Edema in Nephrotic Syndrome: A Review of Clinical Studies A crossover trial in children with nephrotic syndrome and refractory edema found that combining albumin with furosemide roughly doubled urine output and produced significantly more weight loss compared to furosemide alone.22PubMed. Randomized cross-over trial comparing albumin and frusemide infusions in nephrotic syndrome
That said, published studies on the albumin-plus-diuretic combination report conflicting results overall, and expert reviews generally recommend reserving this approach for patients whose edema has resisted maximum diuretic doses or who have very low albumin levels.23PubMed. Combined furosemide and human albumin treatment for diuretic-resistant edema It is not a first-line strategy but a rescue option when standard treatment stalls.
Plasma Exchange and Specialized Procedures
Therapeutic plasma exchange is a procedure that removes a patient’s plasma and replaces it with a substitute fluid, used in conditions like certain autoimmune disorders and neurological emergencies. Albumin solution is one of the most common replacement fluids for this purpose, because it fills the volume gap without introducing the immune proteins that come with donated plasma, which can cause allergic reactions or other complications.24Journal of Clinical Apheresis. Refinement of Replacement Fluid Using Human Serum Albumin Preparation to Enhance Biocompatibility in Therapeutic Plasma Exchange When the goal is simply to remove harmful antibodies or toxins from the blood rather than replace clotting factors, albumin is the preferred choice.
Concentration Matters More Than You Might Think
Albumin comes in two main concentrations: 5 percent (iso-oncotic, similar to the concentration in normal blood) and 20-25 percent (hyper-oncotic, much more concentrated). They serve different purposes. The 5 percent version is used primarily for volume replacement, behaving somewhat like a direct blood volume top-up. The concentrated version pulls fluid from tissues back into the bloodstream, making it useful for patients with edema or those who cannot tolerate large fluid volumes.
But higher concentration is not always better. Experimental work suggests that hyper-oncotic albumin can alter pressure dynamics inside the kidneys in ways that reduce filtration and may even cause cellular damage in kidney tubules.25PubMed Central. Effects of crystalloid, hyper-oncotic albumin, and iso-oncotic albumin on lung and kidney damage in experimental acute lung injury The same study found that iso-oncotic albumin was associated with less kidney injury than the concentrated form. This is a reminder that albumin dosing requires clinical judgment, not a “more is better” approach.
Why Not Give Albumin to Everyone With Low Levels?
A common misconception is that a low albumin level on a blood test is, by itself, a reason to infuse albumin. In reality, low albumin is more often a marker of illness severity than a direct cause of problems. Inflammation, malnutrition, liver failure, and kidney disease all drive albumin down, and simply pumping albumin into the bloodstream does not fix the underlying cause. The circulating albumin you infuse gets broken down or redistributed, so the level often drops back down unless the root problem is addressed.
This is especially relevant in neonatal care. Premature babies frequently have low albumin levels, and the instinct to correct that number with an infusion is understandable. But a Cochrane review found no evidence from randomized trials that routine albumin infusion in preterm newborns with low albumin reduces death or illness.26PubMed Central. Albumin infusion for low serum albumin in preterm newborn infants A separate review noted that albumin is often prescribed in neonatal intensive care for conditions like low blood pressure, high bilirubin, and post-surgical fluid management, but the evidence behind many of these uses has not been validated, and albumin can cause harm when misused.27PubMed. Uses and misuses of albumin during resuscitation and in the neonatal intensive care unit The takeaway is that albumin infusion works best when given for a specific clinical indication, not simply to normalize a lab value.
Cost and Supply Constraints
Albumin is derived from pooled human plasma donations, with industrial processing that pools thousands of individual donations.28PubMed Central. Modern plasma fractionation That production process makes it inherently expensive compared to crystalloid solutions, which are manufactured synthetically. In resource-limited settings, cost is a real barrier to using albumin even where the evidence supports it.29Drugs in Context. Cost-effectiveness of albumin in the treatment of decompensated cirrhosis in resource-limited healthcare settings This is why the question of which patients genuinely benefit matters so much: blanket albumin use across an entire ICU would be prohibitively expensive and largely unjustified, while targeted use in SBP, large-volume paracentesis, or septic shock can save lives in a cost-effective way.
Albumin as a Drug Delivery Vehicle
A completely different frontier for albumin has nothing to do with IV infusion in hospitals. Pharmaceutical researchers have been exploiting albumin’s natural properties to build nanoparticle drug delivery systems, particularly for cancer therapy. Albumin-based nanoparticles take advantage of the fact that tumors naturally take up albumin through specific receptor pathways. The surface of albumin molecules also offers convenient chemical attachment points for drugs and targeting molecules.30PubMed Central. Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance These nanoparticles are biocompatible and biodegradable, and they can be prepared without harsh chemicals.31PubMed Central. Protein nanoparticles as drug delivery carriers for cancer therapy The most commercially successful example is nab-paclitaxel, a chemotherapy drug bound to albumin nanoparticles, which is now a standard treatment for several cancers. This application turns albumin from a supportive infusion into an active participant in treatment.